Abstract
rhC1-INH is indicated in the US for the treatment of acute HAE attacks in adolescents/adults; it is also indicated for children aged ≥2 years in the EU. There is a need to gain further insight into pharmacokinetic (PK) differences in functional C1-INH levels by age (ie, children, adolescents, and adults). The current aim was to employ population PK modeling to predict C1-INH levels following rhC1-INH administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
